Alzheimer’s Association Launches New Open-Access Journal

Alzheimer’s Association Launches New Open-Access Journal
The existence of specific and reliable biomarkers for Alzheimer's disease are crucial to identifying individuals to enroll in clinical trials so that drugs can be tested and diseases can be detected as soon as possible. Facilitating clinical trial enrollment allows studies that are researching and developing therapies that stop or slow Alzheimer's disease progression to be completed and delivered as quickly as possible. The Alzheimer's Association and the Alzheimer's & Dementia: The Journal of the Alzheimer's Association have recently introduced a new open access journal to acknowledge the relevance of biomarkers in order to advance investigation in Alzheimer's disease. The new journal will serve as an active channel specialized in sharing scientific discoveries. "Due to an increasing number of submissions, Alzheimer's & Dementia is unable to publish all the potentially impactful reports submitted for consideration. Creating these new open access journals under the Alzheimer's & Dementia umbrella creates opportunities for valuable research to be published, especially in key, catalytic areas of the field, such as diagnosis and assessment," explained Zaven S. Khachaturian, the Alzheimer's & Dementia editor-in-chief. Alzheimer's & Dementia: DADM will be focused on novel research that reports discoveries, development, validation of assays, technologies, instruments and algorithmic approaches that might lead to accurate identification of individuals who are at r
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *